Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.

Share:
More In Business
Be Prepared for No Rate Cuts in 2024
With stubborn inflation sticking at about 2.8%, there’s a chance that the Fed won’t cut rates this year. That might be the smarter choice in the long run.
Load More